Research firm IMARC Group expects this market to grow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report & Forecast: 2012-2016”.
New Report Analyzes the Potential of Therapeutic Monoclonal Antibodies in India
New Report Analyzes the Potential of Therapeutic MonoclonalAntibodies in IndiaResearch firm IMARC Group expects this market to grow at a CAGR of around 26% during2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report &Forecast: 2012-2016”.A huge patient pool, increasing prevalence of health insurance, strong biosimilar manufacturingcapabilities and a largely unpenetrated market are expected to be the catalysts in driving themarket for monoclonal antibodies in India. Research firm IMARC Group expects this market togrow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “IndianMonoclonal Antibodies Market Report & Forecast: 2012-2016”.According to an analyst at IMARC Group, “India’s poor historical track record in Intellectualproperty protection has resulted in many Indian companies acquiring strong reverse engineeringskills. The Indian generic industry provides generic drugs not only to India but to the entireworld. India currently has more FDA approved manufacturing facilities than any other countryoutside the US. Globally there are only 2 approved biosimilar monoclonal antibodies withReditux (Rituximab) (developed and manufactured by Dr. Ready’s, an Indian genericmanufacturer) being one of them. As a result, India and its biosimilar manufacturers can beregarded as the front runners in the global biosimilar antibody market race”.Key Aspects Analyzed in this Report: Understanding the strengths, weaknesses, opportunities and challenges in the Indian monoclonal antibodies market Understanding the technological considerations and regulatory factors in the Indian monoclonal antibodies market Evaluation and identification of monoclonal antibodies based on the sources from which they are derived and on the targets against which they act Understanding the key regulations for registering, manufacturing and importing monoclonal antibodies in India
Evaluating the patent details of all globally marketed monoclonal antibodies in India, US and Europe Identifying the patentee name and patent numbers of all in-market monoclonal antibodies in India, US and Europe Identifying the monoclonal antibodies that are patent protected in India, US and Europe and those that are not Estimating the patent expiries of various monoclonal antibodies in India, US and Europe Comprehensive situation analysis of the Indian monoclonal antibodies market Analyzing current and future sales of monoclonal antibodies in India Identifying all globally launched monoclonal antibodies and understanding their performance and launch status in India Analyzing the global and Indian monoclonal antibodies market by Indication Evaluation of the top selling monoclonal antibodies Key biosimilar antibody development programmes in India and abroadTable of Contents1 Market Definitions & Methodology2 Executive Summary3 Therapeutic Antibodies Market in India 3.1 Industry Analysis 3.1.1 Strengths 3.1.2 Weaknesses 3.1.3 Opportunities 3.1.4 Threats 3.2 Technological & Regulatory Assessment 3.2.1 Technological Assessment 3.2.2 Regulatory Assessment
3.3 Patent Details of Various Monoclonal Antibodies: US, Europe & India 3.4 Market Analysis 3.4.1 Current & Future Sales Trends 3.4.2 Sales Breakup by Molecule 3.4.3 Sales by Indication 3.5 Evaluation of Top Monoclonal Antibodies 22.214.171.124 Avastin 126.96.36.199 Herceptin 188.8.131.52 Rituxan/Mabthera 184.108.40.206 Remicade 220.127.116.11 Humira 3.6 Biosimilar Case Studies 3.6.1 Reditux 3.6.2 Grafeel 3.7 Key Indian & Foreign Biosimilar Antibody Development ProgrammesTo buy the complete report or to get a free sample, please contact: IMARC Group Asia Email: firstname.lastname@example.org Phone: +91-120-415-5099 IMARC Group North America Email: email@example.com Phone: +1-631-791-1145
IMARC Group Europe, Middle East & AfricaEmail:firstname.lastname@example.orgPhone: +44-702-409-7331To know more please visit: http://www.imarcgroup.com/